ECM
BIOL

Evergreen Capital Management’s Biolase, Inc. BIOL Stock Holding History

Evergreen Capital Management’s Portfolio BIOL Stock Details BIOL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1
Closed -$7K – 371
2017
Q4 		$7K Buy
+1
New +$7.03K ﹤0.01% 233

Other funds holding BIOL

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
TA
Teton Advisors Rye, New York $142M AUM 42.07% 1-Year Est. Return
TMC
Trellus Management Company Delray Beach, Florida $72.8M AUM 4.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Evergreen Capital Management's BIOL Position: Q1 2018 in Review

Evergreen Capital Management sold out of Biolase, Inc. (BIOL) in Q1 2018, closing a stake of 1 share — an estimated $7K sold.

Evergreen Capital Management first reported a position in BIOL in Q4 2017 and held it in 1 quarter. The position peaked at $7K in Q4 2017. 26 funds tracked by Wall St. Rank hold BIOL as of Q1 2018.

  • Evergreen Capital Management reported no remaining Biolase, Inc. position as of Q1 2018 after selling out during the quarter.
  • Evergreen Capital Management sold 1 Biolase, Inc. share in Q1 2018, an estimated $7K.
  • Evergreen Capital Management first reported a position in Biolase, Inc. in Q4 2017 and held it in 1 quarter.
  • Evergreen Capital Management's Biolase, Inc. position peaked at $7K in Q4 2017.
  • 26 funds tracked by Wall St. Rank held Biolase, Inc. as of Q1 2018.

Based on Evergreen Capital Management's 13F filing for Q1 2018, filed 10 May 2018.